Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

60.10USD
1:32am IST
Change (% chg)

$-0.74 (-1.22%)
Prev Close
$60.84
Open
$60.58
Day's High
$60.69
Day's Low
$59.85
Volume
735,551
Avg. Vol
1,038,292
52-wk High
$68.74
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $58,170.68
Shares Outstanding(Mil.): 959.35
Dividend: 0.34
Yield (%): 2.21

Financials

  TEVA.N Industry Sector
P/E (TTM): 18.93 36.11 38.09
EPS (TTM): 3.21 -- --
ROI: 7.88 16.12 15.45
ROE: 12.09 16.91 16.49
Search Stocks

U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil

WASHINGTON - U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday.

28 May 2015

UPDATE 2-U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil

WASHINGTON, May 28 - U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday.

28 May 2015

U.S. settles 'pay for delay' fight with drugmaker Cephalon

WASHINGTON, May 28 - U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil, the Federal Trade Commission said on Thursday.

28 May 2015

Teva discloses 1.35 pct stake in target Mylan

May 27 - Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV , saying the purchase underscored its commitment to buy Mylan as soon as possible.

28 May 2015

Exclusive: Mylan chairman tells investors he would consider buying Teva

- Generics drugmaker Mylan NV , which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd , but would consider buying that company down the road, Mylan Executive Chairman Robert Coury told investors this week.

09 May 2015

UPDATE 2-Top California court revives Cipro antitrust case

May 7 - California's highest court on Thursday revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment.

08 May 2015

BRIEF-Stada targets forex-adj Russia sales growth of 17-20 pct

* Says expects Russia business to bottom out in Q4 at the latest

07 May 2015

U.S. top court rejects hepatitis B drug patent case

WASHINGTON - The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B.

04 May 2015

U.S. top court rejects hepatitis B drug patent case

WASHINGTON, May 4 - The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B.

04 May 2015

Deals of the day- Mergers and acquisitions

April 30 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

01 May 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF96.50 -1.95
Biogen Inc (BIIB.OQ) $396.27 -3.83

Earnings vs. Estimates

Search Stocks